Weekly diabetes jab shown to reduce blood-sugar levels and body weight
Summary
A new weekly injection called retatrutide has been tested in people with type 2 diabetes. It showed greater reductions in blood sugar and body weight compared to a placebo over 40 weeks, by targeting three hormones that regulate appetite, blood sugar, and energy use.Key Facts
- Retatrutide acts like three gut hormones: GLP-1, GIP, and glucagon.
- The trial involved 930 adults with type 2 diabetes not already on diabetes medication.
- After 40 weeks, participants lost between 11.5% and 15.3% of their body weight on retatrutide, compared to 2.6% with placebo.
- Blood sugar levels (measured by HbA1c) fell by about 1.7-1.9 points with retatrutide versus 0.8 with placebo.
- Retatrutide also improved cholesterol and blood pressure.
- Side effects were mostly mild to moderate, with digestive symptoms being most common.
- Some experts say more studies are needed to compare retatrutide to existing drugs like semaglutide or tirzepatide.
- The drug could help people needing stronger treatment for type 2 diabetes, but lifestyle changes remain important.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.